Psychedelic Therapeutics Market Size to Hit USD 11.03 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Psychedelic Therapeutics Market

5.1. COVID-19 Landscape: Psychedelic Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Psychedelic Therapeutics Market, By Molecule / Class

8.1. Psychedelic Therapeutics Market Revenue and Volume Forecast, by Molecule / Class

8.1.1. Psilocybin / PsilocinPsilocybin

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. MDMA

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Lysergide / LSD

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Tryptamines

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Iboga Alkaloids

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Ketamine Class

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. Next-gen 5-HT2A modulators / psychoplastogens

8.1.7.1. Market Revenue and Volume Forecast

Chapter 9. Global Psychedelic Therapeutics Market, By Source / Synthesis Route

9.1. Psychedelic Therapeutics Market Revenue and Volume Forecast, by Source / Synthesis Route

9.1.1. Fully synthetic

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Biosynthetic / fermentation

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Engineered microbial pathways

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Botanical / fungal extraction (limited)

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Psychedelic Therapeutics Market, By Form / Solid-State & Grade

10.1. Psychedelic Therapeutics Market Revenue and Volume Forecast, by Form / Solid-State & Grade

10.1.1. Salt forms

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Base forms

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Polymorph / crystal forms

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Micronized / particle-size controlled grades

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Psychedelic Therapeutics Market, By End Use

11.1. Psychedelic Therapeutics Market Revenue and Volume Forecast, by End Use

11.1.1. Branded Rx developers/sponsors

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Clinic networks / licensed compounding

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. State-regulated service providers

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Academic / investigator-initiated programs

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Psychedelic Therapeutics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Molecule / Class

12.1.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.1.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.1.4. Market Revenue and Volume Forecast, by End Use

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.1.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.1.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.1.5.4. Market Revenue and Volume Forecast, by End Use

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Molecule / Class

12.1.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.1.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.1.6.4. Market Revenue and Volume Forecast, by End Use

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Molecule / Class

12.2.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.2.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.2.4. Market Revenue and Volume Forecast, by End Use

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.2.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.2.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.2.5.4. Market Revenue and Volume Forecast, by End Use

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Molecule / Class

12.2.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.2.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.2.6.4. Market Revenue and Volume Forecast, by End Use

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Molecule / Class

12.2.7.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.2.7.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.2.7.4. Market Revenue and Volume Forecast, by End Use

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Molecule / Class

12.2.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.2.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.2.8.4. Market Revenue and Volume Forecast, by End Use

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Molecule / Class

12.3.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.3.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.3.4. Market Revenue and Volume Forecast, by End Use

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.3.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.3.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.3.5.4. Market Revenue and Volume Forecast, by End Use

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Molecule / Class

12.3.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.3.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.3.6.4. Market Revenue and Volume Forecast, by End Use

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Molecule / Class

12.3.7.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.3.7.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.3.7.4. Market Revenue and Volume Forecast, by End Use

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Molecule / Class

12.3.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.3.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.3.8.4. Market Revenue and Volume Forecast, by End Use

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Molecule / Class

12.4.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.4.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.4.4. Market Revenue and Volume Forecast, by End Use

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.4.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.4.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.4.5.4. Market Revenue and Volume Forecast, by End Use

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Molecule / Class

12.4.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.4.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.4.6.4. Market Revenue and Volume Forecast, by End Use

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Molecule / Class

12.4.7.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.4.7.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.4.7.4. Market Revenue and Volume Forecast, by End Use

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Molecule / Class

12.4.8.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.4.8.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.4.8.4. Market Revenue and Volume Forecast, by End Use

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.5.4. Market Revenue and Volume Forecast, by End Use

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Molecule / Class

12.5.5.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.5.5.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.5.5.4. Market Revenue and Volume Forecast, by End Use

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Molecule / Class

12.5.6.2. Market Revenue and Volume Forecast, by Source / Synthesis Route

12.5.6.3. Market Revenue and Volume Forecast, by Form / Solid-State & Grade

12.5.6.4. Market Revenue and Volume Forecast, by End Use

Chapter 13. Company Profiles

13.1. Compass Pathways plc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerMolecule / Classance

13.1.4. Recent Initiatives

13.2. MindMed Broad pipeline

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerMolecule / Classance

13.2.4. Recent Initiatives

13.3. MindMed Broad pipeline

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerMolecule / Classance

13.3.4. Recent Initiatives

13.4. Cybin Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerMolecule / Classance

13.4.4. Recent Initiatives

13.5. Johnson & Johnson / Janssen

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerMolecule / Classance

13.5.4. Recent Initiatives

13.6. Pfizer

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerMolecule / Classance

13.6.4. Recent Initiatives

13.7. Delix Therapeutics

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerMolecule / Classance

13.7.4. Recent Initiatives

13.8. Beckley Psytech

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerMolecule / Classance

13.8.4. Recent Initiatives

13.9. Eleusis / Beckley (via Eleusis)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerMolecule / Classance

13.9.4. Recent Initiatives

13.10. Abbott

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerMolecule / Classance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The psychedelic therapeutics market size is expected to increase from USD 2.94 billion in 2025 to USD 11.03 billion by 2034.

The psychedelic therapeutics market is expected to grow at a compound annual growth rate (CAGR) of around 15.82% from 2025 to 2034.

The major players in the psychedelic therapeutics market include Eleusis / Beckley (via Eleusis), Beckley Psytech, Delix Therapeutics, Pfizer, Johnson & Johnson / Janssen, Cybin Inc., ATAI Life Sciences, and MindMed.

The driving factors of the psychedelic therapeutics market are the pidly emerging as a transformative frontier in mental health treatment, driven by growing clinical validation and regulatory momentum for psychedelic-assisted therapies.

North America region will lead the global psychedelic therapeutics market during the forecast period 2025 to 2034.